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Objectives The purpose of this study was to determine the predictors of major bleeding and the impact of major bleeding
on outcomes, including mortality, in acute coronary syndromes (ACS).
Background Whether major bleeding independently predicts mortality in patients with ACS undergoing an early invasive
strategy is undefined.
Methods Patients (n  13,819) with moderate- and high-risk ACS were randomized to heparin (unfractionated or enox-
aparin) plus glycoprotein IIb/IIIa inhibition (GPI), bivalirudin plus GPI, or bivalirudin monotherapy (plus provi-
sional GPI). Logistic regression was used to determine predictors of 30-day major bleeding and mortality.
Results Major bleeding rates in patients treated with heparin plus GPI were higher versus bivalirudin monotherapy (5.7%
vs. 3.0%, p  0.001) and similar versus bivalirudin plus GPI (5.7% vs. 5.3%, p  0.38). Independent predictors
of major bleeding were advanced age, female gender, diabetes, hypertension, renal insufficiency, anemia, no
prior percutaneous coronary intervention, cardiac biomarker elevation, ST-segment deviation 1 mm, and treat-
ment with heparin plus GPI versus bivalirudin monotherapy. Patients with major bleeding had higher 30-day
rates of mortality (7.3% vs. 1.2%, p  0.0001), composite ischemia (23.1% vs. 6.8%, p  0.0001), and stent
thrombosis (3.4% vs. 0.6%, p  0.0001) versus those without major bleeding. Major bleeding was an indepen-
dent predictor of 30-day mortality (odds ratio 7.55, 95% confidence interval 4.68 to 12.18, p  0.0001).
Conclusions Major bleeding is a powerful independent predictor of 30-day mortality in patients with ACS managed invasively.
Several factors independently predict major bleeding, including treatment with heparin plus GPI compared with
bivalirudin monotherapy. Knowledge of these findings might be useful to reduce bleeding risk and improve out-
comes in ACS. (J Am Coll Cardiol 2007;49:1362–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.027N
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March 27, 2007:1362–8 Major Bleeding in ACSntithrombotic therapy is an important component of the
anagement of patients with acute coronary syndromes
ACS) (unstable angina or non–ST-segment elevation myo-
ardial infarction) (1). Although advances in antithrombotic
herapy have reduced rates of ischemic events, they typically
ave increased the risk of bleeding complications (2,3), and
ata suggest an adverse relationship between bleeding and
utcomes (4,5).
Bivalirudin has demonstrated anti-ischemic efficacy and
avorable bleeding complication rates in percutaneous cor-
nary intervention (PCI) and ACS (6,7). In the REPLACE
Randomized Evaluation of PCI Linking Angiomax to
educed Clinical Events)-2 trial, bivalirudin (plus provi-
ional glycoprotein IIb/IIIa inhibition [GPI]) was noninfe-
ior to unfractionated heparin plus planned GPI in sup-
ressing ischemic events, while markedly reducing bleeding
6). In the ACUITY (Acute Catheterization and Urgent
ntervention Triage strategY) trial, bivalirudin (plus provi-
ional GPI) resulted in similar 30-day composite ischemic
vent rates, less bleeding, and superior net clinical outcomes,
ompared with heparin (unfractionated or enoxaparin) plus
PI in ACS (7).
This analysis examines the predictors of major bleeding
nd its impact on 30-day outcomes, including mortality, in
he ACUITY trial.
ethods
tudy design. In the ACUITY trial (7), 13,819 patients
ith moderate- and high-risk ACS were randomly assigned
n open-label fashion to heparin (unfractionated or enox-
parin) plus GPI, bivalirudin plus GPI, or bivalirudin
onotherapy (plus provisional GPI). Unfractionated hepa-
in was administered intravenously as a 60 IU/kg bolus plus
2 IU/kg/h infusion, to achieve an activated partial throm-
oplastin time of 50 to 75 s before angiography and an
ctivated clotting time of 200 to 250 s during PCI. The
edian maximum activated clotting time among patients
ndergoing PCI with unfractionated heparin was 239 s
interquartile range 211 to 291 s) (7). Enoxaparin was
dministered 1 mg/kg subcutaneously twice a day, with a
.3 mg/kg intravenous bolus immediately before PCI, if the
ast subcutaneous dose was 8 h earlier or 0.75 mg/kg if
16 h earlier. Bivalirudin was administered intravenously as
0.1 mg/kg bolus plus 0.25 mg/kg/h infusion, with a bolus
f 0.5 mg/kg and an increase in the infusion to 1.75
g/kg/h before PCI. Antithrombotic monitoring was not
erformed for enoxaparin or bivalirudin. Antithrombins
ere routinely discontinued after angiography or after PCI.
he GPI group patients were randomized again (2  2
actorial design) to either initiation upstream or deferred
before PCI). Provisional GPI was permitted in deferred
PI or bivalirudin monotherapy patients for severe break-
hrough ischemia and during PCI in bivalirudin mono-
herapy patients for prespecified criteria. The GPI was
dministered per labeling and continued 12 to 18 h after hCI. Coronary angiography was
equired within 72 h, with tri-
ge to PCI, coronary artery by-
ass graft surgery (CABG), or
edical management. Aspirin
300 to 325 mg orally or 250 to
00 mg intravenously) was ad-
inistered daily during hospital
tays. Thienopyridine dosing and
iming were left to investigator
iscretion; however, the protocol
equired a clopidogrel loading
ose of 300 mg 2 h after
CI, and 75 mg daily was rec-
mmended for 1 year in coronary
rtery disease patients. The institutional review or ethics
oard at each center approved the study, and patients signed
ritten, informed consent.
nd points and statistical methods. The ACUITY study
as powered for 3 primary 30-day end points: composite
schemia, major bleeding (not CABG-related), and net
linical outcomes. A blinded clinical events committee
djudicated all primary and secondary end points. Major
leeding (not CABG-related) was defined as: intracranial or
ntraocular; access site bleeding requiring intervention;
5-cm diameter hematoma; hemoglobin reduction of 4
/dl without or 3 g/dl with an overt source; reoperation
or bleeding; or blood product transfusion. All analyses are
ntention to treat. Chi-square test was used for categorical
ariables, unless the observation in any cell was 5, in
hich the Fisher exact test was used. Continuous variables
ere tested with the Wilcoxon rank sum test. Medians and
nterquartile ranges are presented for continuous variables.
ime-to-event distributions are displayed according to the
aplan-Meier method and compared with log-rank test.
he p values are given for informational purposes and no
ultiplicity adjustment was done. Predictors of major
leeding and 30-day mortality were identified with logistic
egression analyses. Potential predictors were selected with
tepwise, forward, and backward procedures. For each
rocedure, a prediction factor entered into the model with p
0.20 and retained with p  0.10. The final model
ncludes all predictors selected by at least 1 of the proce-
ures. The p values, odds ratios (ORs), and corresponding
-sided 95% confidence interval (CI) for predictors are
resented. Statistical analyses were performed by SAS
ersion 8.2 (SAS Institute Inc., Cary, North Carolina).
esults
atient characteristics. Of 13,819 patients, 644 (4.7%) ex-
erienced major bleeding. Patients with major bleeding were
lder, more likely female, and of lower body weight. They were
ore likely to have diabetes, hypertension, anemia, and renal
nsufficiency and less likely to have hyperlipidemia, smoke, or
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass graft surgery
GRACE  Global Registry
of Acute Coronary Events
GPI  glycoprotein IIb/IIIa
inhibitor/inhibition
MI  myocardial infarction
PCI  percutaneous
coronary interventionave prior PCI. Patients with major bleeding more often
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Major Bleeding in ACS March 27, 2007:1362–8resented with cardiac biomarker elevation or ST-segment
eviation of1 mm. Compared with the group without major
leeding, the treatment strategy of patients in the major
leeding group was more commonly PCI and less commonly
ABG or medical therapy (Table 1).
ntithrombotic medications and major bleeding. Major
leeding occurred less frequently in patients treated with
ivalirudin monotherapy versus heparin plus GPI. How-
ver, major bleeding was similar in patients treated with
haracteristics of Patients With and Without Major Bleeding
Table 1 Characteristics of Patients With and Without Major Bl
Major Bleedin
n  644 (4.7
Age (median [range], yrs) 69 [37–9
Weight (median [IQR], kg) 79.5 [68, 9
Age  65 yrs 399 (62.0
Age  75 yrs 222 (34.5
Female 318 (49.4
Diabetes 220/637 (34.5
Anemia* 193/615 (31.4
Hypertension 472 (73.3
Hyperlipidemia 337/633 (53.2
Current smoker 156/632 (24.7
Prior myocardial infarction 185/634 (29.2
Prior percutaneous coronary intervention 188/633 (29.7
Prior coronary artery bypass surgery 114/643 (17.7
Renal insufficiency† 226/606 (37.3
Baseline cardiac biomarker elevation 414/608 (68.1
Baseline ST-segment deviation  1 mm 290 (45.0
Treatment strategy
Percutaneous coronary intervention 462 (71.7
Coronary artery bypass surgery 51 (7.9)
Medical management 131 (20.3
Anemia was defined as baseline hemoglobin 13 g/dl in men and 12 g/dl in women. †Renal
quation.
IQR  interquartile range.
ypes of Major Bleeding by Treatment Group
Table 2 Types of Major Bleeding by Treatment Group
Heparin (Unfractionated
or Enoxaparin) Plus a
Glycoprotein IIb/IIIa
Inhibitor (n  4,603)
Bivalirudi
Glycoprote
Inhibitor (n
Major bleeding (not CABG-related)
(primary end point)
262 (5.7%) 243 (5.
Intracranial 3 (0.07%) 3 (0.
Retroperitoneal 24 (0.5%) 26 (0.
Access site bleeding 117 (2.5%) 117 (2.
Requiring intervention or surgery 24 (0.5%) 28 (0.
Hematoma 5 cm 102 (2.2%) 101 (2.
Hemoglobin decrease 3 g/dl
with overt source
102 (2.2%) 83 (1.
Hemoglobin decrease 4 g/dl
without overt source
39 (0.8%) 33 (0.
Blood transfusion 125 (2.7%) 119 (2.
Reoperation for bleeding 2 (0.04%) 5 (0.
Thrombocytopenia (acquired)‡ 511 (11.1%) 497 (10
Comparison between bivalirudin plus a glycoprotein IIb/IIIa inhibitor and heparin (unfractionated
eparin (unfractionated or enoxaparin) plus a glycoprotein IIb/IIIa inhibitor. ‡Platelet count  150,000 c
CABG  coronary artery bypass surgery.ivalirudin plus GPI versus heparin plus GPI (Table 2).
atients with major bleeding more frequently received GPI
efore angiography. The timing of aspirin, thienopyridine,
nd antithrombin administration related to angiography did
ot influence major bleeding, nor did several other time
ntervals (Table 3).
redictors of major bleeding. Independent predictors of
ajor bleeding were: age75 years, female gender, anemia,
enal insufficiency, diabetes, hypertension, no prior PCI,
g
No Major Bleeding
n  13,175 (95.3%) p Value
62 [20–93] 0.0001
84.0 [73, 95] 0.0001
5,825 (44.2) 0.0001
2,219 (16.8) 0.0001
3,839 (29.1) 0.0001
3,632/13,072 (27.8) 0.0002
2,008/12,425 (16.2) 0.0001
8,740/13,103 (66.7) 0.0005
7,410/12,907 (57.4) 0.04
3,787/12,925 (29.3) 0.01
4,037/12,849 (31.4) 0.24
5,132/13,050 (39.3) 0.0001
2,351/13,131 (17.9) 0.91
2,242/12,334 (18.2) 0.0001
7,138/12,106 (59.0) 0.0001
4,535/13,160 (34.5) 0.0001
7,327 (55.6) 0.0001
1,488 (11.3) 0.008
4,360 (33.1) 0.0001
iency was defined as a creatinine clearance of 60 ml/min as calculated by the Cockcroft-Gault
a
IIIa
04)
Risk Ratio
[95%
Confidence
Interval]
p1
Value*
Bivalirudin
Monotherapy
(n  4,612)
Risk Ratio
[95%
Confidence
Interval]
p2
Value†
0.93
[0.78–1.10]
0.38 139 (3.0%) 0.53
[0.43–0.65]
0.0001
1.00§ 3 (0.07%) 1.00§
0.78 7 (0.2%) 0.01
1.00 38 (0.8%) 0.0001
0.58 14 (0.3%) 0.10
0.94 32 (0.7%) 0.0001
0.16 45 (1.0%) 0.0001
0.48 33 (0.7%) 0.47
0.70 75 (1.6%) 0.0003
0.45§ 4 (0.1%) 0.69§
0.64 457 (9.9%) 0.06
xaparin) plus a glycoprotein IIb/IIIa inhibitor. †Comparison between bivalirudin monotherapy and
3eedin
g
%)
5]
2]
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
insufficn Plus
in IIb/
 4,6
3%)
07%)
6%)
5%)
6%)
2%)
8%)
7%)
6%)
1%)
.8%)
or eno
ells/mm in patients without baseline thrombocytopenia. §Fisher’s exact test.
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March 27, 2007:1362–8 Major Bleeding in ACST-segment deviation 1 mm, and cardiac biomarker
levation (Fig. 1). Treatment with heparin plus GPI versus
ivalirudin monotherapy also independently predicted ma-
or bleeding.
ajor bleeding and mortality. Patients with versus with-
ut major bleeding had higher rates of 30-day mortality
7.3% vs. 1.2%, p 0.0001) (Fig. 2). Major bleeding was an
ndependent predictor of 30-day mortality (OR 7.55, 95%
Figure 1 Independent Predictors of Major Bleeding
*Anemia was defined as baseline hemoglobin 13 g/dl in men and 12 g/dl in w
calculated by the Cockcroft-Gault equation. ‡Unfractionated heparin or enoxaparin
PCI  percutaneous coronary intervention.
ntithrombotic Medications in Patients With and Without Major Bl
Table 3 Antithrombotic Medications in Patients With and With
Major Ble
n  644/13,8
Time intervals (median [IQR])
Admission to angiography* (h) 20.72 [6
Admission to randomization (h) 6.75 [2
Randomization to antithrombin study drug
initiation† (h)
0.57 [0
Antithrombin study drug† to angiography‡ (h) 4.00 [0
Antithrombin
Before randomization
Unfractionated heparin 275 (4
Enoxaparin 177 (2
Aspirin use or administration prior to angiography 610/622 (9
Thienopyridine use or administration prior to
angiography
415/620 (6
Glycoprotein IIb/IIIa inhibitor administration prior
to randomization
48 (7
Glycoprotein IIb/IIIa inhibitor administration prior
to angiography§
Eptifibatide 192 (2
Tirofiban 91 (1
Abciximab 2 (0
ontinuous variables are expressed as median [interquartile range]. *Data are not normally distrib
ot receiving the study antithrombin drug prior to randomization. ‡In patients undergoing percu
dministered post-randomization, but prior to angiography. Fisher’s exact test.
IQR  interquartile range.I 4.68 to 12.18; p  0.0001). Other independent predic-
ors of 30-day mortality included: age 75 years, left
entricular ejection fraction 50%, prior stroke, ST-
egment deviation 1 mm, cardiac biomarker elevation,
reatment strategy of CABG (vs. PCI), and myocardial
nfarction (MI) (Fig. 3).
ajor bleeding and other outcomes. Patients with major
leeding had higher rates of 30-day composite ischemic
. †Renal insufficiency was defined as a creatinine clearance 60 ml/min as
confidence interval; GPI  glycoprotein IIb/IIIa inhibitor; OR  odds ratio;
g
ajor Bleeding
.7%)
No Major Bleeding
n  13,175/13,819 (95.3%) p Value
.7] 19.57 [7.0, 28.6] 0.05
.0] 6.0 [2.0, 15.3] 0.16
] 0.55 [0.3, 1.0] 0.70
.2] 3.82 [1.0, 18.3] 0.51
5,363/13,145 (40.8) 0.34
3,348/13,147 (25.5) 0.25
12,704/12,976 (97.9) 0.78
8,262/12,957 (63.8) 0.11
983 (7.5) 0.99
2,761 (21.0) 0.0001
1,506 (11.4) 0.04
32 (0.2) 0.67
o median durations of subgroups do not add up to the duration of the parent group. †In patients
s coronary intervention. §Includes those patients in whom a glycoprotein IIb/IIIa inhibitor wasomen
. CI eedin
out M
eding
19 (4
.8, 33
.2, 16
.3, 1.1
.9, 20
2.7)
7.5)
8.1)
6.9)
.5)
9.8)
4.1)
.3)
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Major Bleeding in ACS March 27, 2007:1362–8vents (death, MI, or unplanned revascularization for isch-
mia), MI, and unplanned revascularization for ischemia
Table 4). Stent thrombosis, thrombocytopenia, and length
f hospital stay (6 vs. 3 days, p  0.0001) were also higher
n patients with versus without major bleeding.
iscussion
ur analysis of 13,819 moderate- and high-risk patients
ith ACS from the ACUITY trial reveals the following: 1)
ajor bleeding occurs in nearly 5% of patients; 2) several
eadily identifiable factors independently predict major
leeding; 3) major bleeding is associated with increased
Figure 2 Kaplan-Meier Curves for Mortality
Figure 3 Independent Predictors of Mortality
CABG  coronary artery bypass surgery; other abbreviations as in Figure 1.0-day ischemic event rates; 4) major bleeding is an inde-
endent predictor of 30-day mortality; and 5) bivalirudin
onotherapy is an independent predictor of lower rates of
ajor bleeding compared with combination therapy with
eparin plus GPI.
Bleeding complications continue to occur frequently in
CS, although rates of bleeding in clinical trials might vary
idely. The current analysis is consistent with the GRACE
Global Registry of Acute Coronary Events) (8), which
eported major bleeding in 3.9% of 24,045 patients, and the
eta-analysis by Eikelboom et al. (5), which reported major
leeding in 2.3% of 34,146 patients.
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March 27, 2007:1362–8 Major Bleeding in ACSWe identified several independent predictors of major
leeding, including advanced age, female gender, diabetes,
ypertension, renal insufficiency, anemia, cardiac biomarker
levation, and ST-segment deviation. These readily identi-
able factors are useful in assessing bleeding risk on presen-
ation, before initiating antithrombotic therapy. Our find-
ngs are consistent with the GRACE registry, which
eported that factors including advanced age, renal insuffi-
iency, history of bleeding, GPI, and PCI independently
redicted major bleeding in unstable angina. Furthermore,
RACE found higher rates of major bleeding in non–ST-
egment elevation MI (4.7%) compared with unstable an-
ina (2.3%) (8). Our analysis confirmed these findings by
evealing that baseline cardiac biomarker elevation and
T-segment deviation were independent predictors of both
ajor bleeding and mortality, suggesting that patients with
ncreased ischemic risk might also have increased bleeding
isk.
Mortality at 30 days was 6-fold higher among patients
ith major bleeding. Major bleeding was the strongest
ndependent predictor of mortality, even more so than MI.
his underscores the adverse impact of major bleeding on
arly mortality and extends the findings from Eikelboom et
l. (5), who reported that major bleeding was independently
ssociated with early mortality in patients predominantly
reated with a conservative strategy (hazard ratio 5.37, 95%
I 3.97 to 7.27, p  0.0001). In addition, our analysis
evealed that 30-day ischemic event rates were 3-fold
igher with major bleeding, occurring in nearly 25% of
atients. Rates of MI, unplanned revascularization for
schemia, and notably, stent thrombosis were all signifi-
antly higher with major bleeding.
Several hypotheses might underlie the association be-
ween bleeding and mortality. First, bleeding often neces-
itates the discontinuation and/or reversal of antithrombotic
herapy, which might result in ischemia, hemodynamic
ecompensation, arrhythmias, stent thrombosis, MI, un-
lanned revascularization, or death (9). Supporting this
ossibility is our finding of a nearly 6-fold higher rate of
tent thrombosis in patients with major bleeding. Second,
Clinical Outcomes in Patients With and Without
Table 4 Clinical Outcomes in Patients With
Maj
n 
Composite ischemia 1
Death from any cause
Myocardial infarction
Q-wave
Non–Q-wave
Unplanned revascularization for ischemia
Percutaneous coronary intervention
Coronary artery bypass surgery
Stent thrombosis
Thrombocytopenia (acquired)* 1
*Platelet count  150,000 cells/mm3 in patients without baseline thleeding with hypovolemia, anemia, and impaired oxygen aarrying capacity might precipitate tachycardia, hypoten-
ion, and congestive heart failure. Third, blood product
ransfusions have been associated with adverse outcomes. In
meta-analysis of 24,112 patients by Rao et al. (10),
ransfusion was associated with an increased hazard for
0-day death (adjusted hazard ratio 3.94, 95% CI 3.26 to
.75, p  0.001). Next, anemia also independently pre-
icted major bleeding in our analysis, and the mechanisms
or this increase in adverse outcomes might include trans-
usion and associated risks, the bleeding complication, and
he etiology of the anemia (11). Lastly, patients with
leeding complications have a more prolonged, complex,
nd costly hospital stay and might require invasive moni-
oring, intra-aortic balloon counterpulsation, intubation,
ndoscopy, anesthesia, and surgical procedures, all of which
ight increase the likelihood of adverse outcomes, includ-
ng death.
In the ACUITY trial, bivalirudin monotherapy (with
.1% provisional GPI use) was associated with signifi-
antly lower rates of major bleeding and similar rates of
schemic events (7) compared with combination therapy
ith heparin plus GPI. These results mirror the
EPLACE-2 PCI trial (6). Collectively, these 2 trials of
early 20,000 patients confirm that the use of bivalirudin,
ompared with heparin plus GPI, is associated with a
ignificant reduction in the risk of bleeding complica-
ions, while maintaining efficacy in reducing ischemic
vents. Importantly, in the ACUITY trial, major bleed-
ng, as defined by the study protocol, was strongly and
ndependently predictive of subsequent mortality, vali-
ating this definition as clinically relevant.
Limitations of the ACUITY trial have been described
7). The current analysis was not prespecified in the original
rial. In addition, multivariable analysis might not ade-
uately account for all relevant factors. This analysis reports
0-day results, and 1-year data might provide additional
nformation. However, given the consistency of these results
ith previous data and the large size of the population, these
ata add significantly to the understanding of the adverse
r Bleeding
Without Major Bleeding
ding
.7%)
No Major Bleeding
n  13,175 (95.3%) p Value
.1) 901 (6.8) 0.0001
) 159 (1.2) 0.0001
.6) 610 (4.6) 0.0001
) 117 (0.9) 0.0001
.6) 495 (3.8) 0.0001
) 289 (2.2) 0.0001
) 221 (1.7) 0.0001
) 73 (0.6) 0.001
) 82 (0.6) 0.0001
.1) 1,329 (10.1) 0.0001
ytopenia.Majo
and
or Blee
644 (4
49 (23
47 (7.3
94 (14
27 (4.2
68 (10
49 (7.6
43 (6.7
10 (1.6
22 (3.4
36 (21ssociation between bleeding and outcomes.
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n summary, in the large-scale ACUITY trial, major bleeding
omplications had a significant, independent, adverse impact
n 30-day outcomes, including mortality, in patients with
CS undergoing early invasive management. Several readily
dentifiable factors independently predicted major bleeding. In
ddition, treatment with bivalirudin rather than heparin plus
PI was an independent predictor of freedom from major
leeding. Knowledge of these findings and a baseline assess-
ent of hemorrhagic risk might facilitate the choice of an
ntithrombotic regimen with a favorable safety and efficacy
rofile, resulting in improved outcomes for patients with ACS.
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